WEBVTT

1
00:00:02.000 --> 00:00:04.384
Two peptides. Two complementary pathways.

2
00:00:04.384 --> 00:00:08.674
One combination. CagriSema brings cagrilintide and semaglutide together, without

3
00:00:08.674 --> 00:00:11.535
turning them into a single molecule.

4
00:00:11.885 --> 00:00:16.277
Developed by Novo Nordisk in Denmark, its clinical story

5
00:00:16.277 --> 00:00:20.668
includes Julio Frias and colleagues' phase two study, published

6
00:00:20.668 --> 00:00:22.132
in twenty twenty-three.

7
00:00:22.132 --> 00:00:26.524
Ninety-two adults with type two diabetes were followed for

8
00:00:26.524 --> 00:00:27.500
thirty-two weeks.

9
00:00:27.850 --> 00:00:30.167
Semaglutide activates GLP-1 receptors.

10
00:00:30.167 --> 00:00:33.642
Cagrilintide engages amylin and calcitonin receptors.

11
00:00:33.642 --> 00:00:37.696
Their complementary signals influence appetite and fullness.

12
00:00:37.696 --> 00:00:42.908
Combining two medicines is different from engineering one peptide

13
00:00:42.908 --> 00:00:45.224
to activate several receptors.

14
00:00:45.574 --> 00:00:49.271
The larger REDEFINE 1 trial followed three thousand four

15
00:00:49.271 --> 00:00:52.967
hundred and seventeen adults without type two diabetes for

16
00:00:52.967 --> 00:00:56.663
sixty-eight weeks. Published in the New England Journal of

17
00:00:56.663 --> 00:01:00.359
Medicine in twenty twenty-five, it tested the combination, each

18
00:01:00.359 --> 00:01:01.591
component, and placebo.

19
00:01:01.941 --> 00:01:06.096
Estimated average weight reduction was twenty point four percent

20
00:01:06.096 --> 00:01:10.250
with the combination, versus three percent with placebo, regardless

21
00:01:10.250 --> 00:01:11.635
of treatment adherence.

22
00:01:11.635 --> 00:01:15.790
A separate analysis assuming adherence gave twenty-two point seven

23
00:01:15.790 --> 00:01:18.560
percent. Those estimates answer different questions.

24
00:01:18.910 --> 00:01:22.961
Nausea, vomiting, diarrhea and constipation were reported.

25
00:01:22.961 --> 00:01:28.171
And in twenty twenty-six, a direct comparison with tirzepatide

26
00:01:28.171 --> 00:01:31.643
did not meet its non-inferiority target.

27
00:01:31.643 --> 00:01:36.274
Greater complexity does not automatically mean better results.

28
00:01:36.624 --> 00:01:41.161
As of October thirteen, twenty twenty-six, Novo still describes

29
00:01:41.161 --> 00:01:42.673
CagriSema as investigational.

30
00:01:42.673 --> 00:01:47.210
Research programmes address obesity and type two diabetes, with

31
00:01:47.210 --> 00:01:49.227
different populations and endpoints.

32
00:01:49.227 --> 00:01:53.764
Its promise rests on evidence, not the number of

33
00:01:53.764 --> 00:01:54.268
ingredients.

34
00:01:55.000 --> 00:01:56.300
Peptides in 2.

35
00:01:56.300 --> 00:01:57.600
World Peptide Foundation.

36
00:01:57.820 --> 00:01:59.399
Every experience matters.